GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Debt-to-Equity

I-MAB (IMAB) Debt-to-Equity : 0.02 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Debt-to-Equity?

I-MAB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.84 Mil. I-MAB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $2.85 Mil. I-MAB's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $198.34 Mil. I-MAB's debt to equity for the quarter that ended in Mar. 2025 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for I-MAB's Debt-to-Equity or its related term are showing as below:

IMAB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.71   Med: 0.02   Max: 0.1
Current: 0.02

During the past 8 years, the highest Debt-to-Equity Ratio of I-MAB was 0.10. The lowest was -0.71. And the median was 0.02.

IMAB's Debt-to-Equity is ranked better than
88.76% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs IMAB: 0.02

I-MAB Debt-to-Equity Historical Data

The historical data trend for I-MAB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Debt-to-Equity Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial - 0.03 0.03 0.02 0.02

I-MAB Quarterly Data
Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.02 0.02 0.02 0.02

Competitive Comparison of I-MAB's Debt-to-Equity

For the Biotechnology subindustry, I-MAB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where I-MAB's Debt-to-Equity falls into.


;
;

I-MAB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

I-MAB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

I-MAB's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB  (NAS:IMAB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


I-MAB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of I-MAB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB Business Description

Traded in Other Exchanges
Address
2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).